EU green-lights Opdivo for melanoma; U.K. plans Bexsero vaccination drive;

> Bristol-Myers Squibb ($BMY) won European approval for its PD-1 immunotherapy Opdivo as a treatment for advanced melanoma, for first-line use as well as for patients who've been treated previously. Release

> The U.K. plans the world's first publicly funded vaccination drive against meningitis B, using Bexsero, the shot developed by Novartis ($NVS) and sold to GlaxoSmithKline ($GSK) in a multibillion-dollar asset swap earlier this year. Report

> A case series published in Diabetes Care advised that SGLT2 diabetes drugs only be used "with great caution" in patients with Type 1 diabetes. Report

> Pfizer's ($PFE) Centrum brand team rolled out a survey in Canada showing Canadians consume as many daily servings of caffeine as fruits and vegetables. Report

> A Texas judge decided that FDA labeling rules didn't pre-empt state regulations on off-label promotions in a case accusing a drugmaker of illegally marketing generic Cordarone for unapproved use. Report

And Finally...  Federal officials charged 11 people in a conspiracy to market millions of bottles of counterfeit 5-hour Energy drinks in the U.S. Report

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.